Gamida Cell launches severe aplastic anemia trial

Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating its CordIn therapy for patients with sickle cell disease. Get the full story at our sister site, Drug Delivery Business News.   The post Gamida Cell launches severe aplastic anemia trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Research & Development Stem Cells Gamida Cell Source Type: news

Related Links:

CONCLUSIONS: Costs due to admissions of RTRs appeared to gradually increase in the long term probably due to the increasing number of admissions and increasing mean age of admitted RTRs. PMID: 30654602 [PubMed - as supplied by publisher]
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
(MedPage Today) -- This week's topics include treatment of multiple sclerosis, malaria treatment, overprescription of antibiotics, and fecal transplant for ulcerative colitis.
Source: MedPage Today Public Health - Category: American Health Source Type: news
CONCLUSION: This review aims to provide an overview of the prevalent trends in the small molecules based regulation of stem cell fate via targeting the Wnt signaling pathway. PMID: 30657051 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Gene therapy and gene editing (functional modification of genes) represent a future direction for treatment of human diseases. Viral vector-based gene delivery or gene transfer is crucial for this purpose. Thoracic and cardiovascular surgery provides great opportunities for translating experimental discoveries toward clinical applications. Awareness of the challenges and limitations of gene delivery is essential for clinician investigators in this field.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Thoracic: Lung Transplant: Letter to the Editor Source Type: research
We read with great interest the article published by Oishi and colleagues,1 which reported that lentiviral-mediated interleukin-10 (IL-10) gene therapy decreased allograft lung rejection. We would like to congratulate Oishi and colleagues1 for this elegant study. In addition, we admire the work that has been done by that laboratory (led by Dr Keshavjee) regarding gene delivery in lung transplantation, and personally we2 share the overall enthusiasm of Oishi and colleagues.1 We would like to add several discussion points that we believe will increase the interest in this emerging topic.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Thoracic: Lung Transplant: Letter to the Editor Source Type: research
ConclusionsEspecially during acute skin and intestinal GvHD, PCT and CRP values strongly and significantly increased beyond the upper normal limits. Simultaneous elevations of PCT and CRP occurred during graft rejection, skin and intestinal GvHD, and sepsis. Taken together, laboratory-chemical analyses of serum PCT in combination with CRP could be a useful discriminative biomarker in the detection of TRAE. Larger, prospective trials are needed, to evaluate these findings.FigureFig. 1. PCT and CRP serum concentrations during acute GvHD, graft rejection, VOD, sepsis, viremia and fungemia. Dotted horizontal lines indicate nor...
Source: Blood - Category: Hematology Authors: Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Source Type: research
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
CONCLUSION: A high prevalence of iron overload in this patient population in Latin American countries indicates that a better diagnosis and management of iron overload is required in these countries. PMID: 29663858 [PubMed - as supplied by publisher]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Conclusions: Alloantibodies should be identified in repeatedly transfused patients and should be given corresponding antigen negative blood unit which will minimize the antibody mediated destruction of transfused red cells.
Source: Asian Journal of Transfusion Science - Category: Hematology Authors: Source Type: research
More News: Anemia | Aplastic Anemia | Bone Marrow Transplant | Clinical Trials | Genetics | Myelodysplastic Syndrome | Sickle Cell Anemia | Stem Cell Therapy | Stem Cells | Study | Transplants